Prokidney (PROK) Income from Non-Controlling Interests (2022)
Prokidney's (PROK) quarterly Income from Non-Controlling Interests came in at -$40.1 million in Q4 2022.
Powered by 
Analysis
Prokidney (PROK) Income from Non-Controlling Interests (2022) Analysis & Trends
Prokidney (PROK) has reported Income from Non-Controlling Interests for 1 consecutive years, with -$40.1 million the latest figure, recorded in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | - |